vs
艾伯维（ABBV）与Aclaris Therapeutics, Inc.（ACRS）财务数据对比。点击上方公司名可切换其他公司
艾伯维的季度营收约是Aclaris Therapeutics, Inc.的12832.4倍（$16.6B vs $1.3M）。艾伯维净利率更高（10.9% vs -1528.6%，领先1539.5%）。艾伯维同比增速更快（10.0% vs -85.9%）。艾伯维自由现金流更多（$4.9B vs $-13.2M）。过去两年艾伯维的营收复合增速更高（16.2% vs -26.5%）
艾伯维是一家总部位于美国伊利诺伊州北芝加哥的制药企业，专注于研发、生产覆盖多种疾病领域的治疗药物，致力于为全球各地患者提供安全有效的临床解决方案，在全球医药行业拥有较高的知名度与影响力。
Aclaris Therapeutics是一家处于临床阶段的生物制药企业，专注于研发针对免疫疾病、炎症性疾病和皮肤病的创新靶向疗法，核心管线覆盖斑秃、白癜风等未满足临床需求领域，致力于为全球相关患者提供新型治疗选择。
ABBV vs ACRS — 直观对比
营收规模更大
ABBV
是对方的12832.4倍
$1.3M
营收增速更快
ABBV
高出96.0%
-85.9%
净利率更高
ABBV
高出1539.5%
-1528.6%
自由现金流更多
ABBV
多$4.9B
$-13.2M
两年增速更快
ABBV
近两年复合增速
-26.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $16.6B | $1.3M |
| 净利润 | $1.8B | $-19.8M |
| 毛利率 | 72.6% | 58.9% |
| 营业利润率 | 27.3% | -1755.5% |
| 净利率 | 10.9% | -1528.6% |
| 营收同比 | 10.0% | -85.9% |
| 净利润同比 | 8354.5% | 79.5% |
| 每股收益（稀释后） | $1.02 | $-0.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABBVACRS
| Q4 25 | $16.6B | $1.3M | ||
| Q3 25 | $15.8B | $3.3M | ||
| Q2 25 | $15.4B | $1.8M | ||
| Q1 25 | $13.3B | $1.5M | ||
| Q4 24 | $15.1B | $9.2M | ||
| Q3 24 | $14.5B | $4.3M | ||
| Q2 24 | $14.5B | $2.8M | ||
| Q1 24 | $12.3B | $2.4M |
净利润ABBVACRS
| Q4 25 | $1.8B | $-19.8M | ||
| Q3 25 | $186.0M | $-14.6M | ||
| Q2 25 | $938.0M | $-15.4M | ||
| Q1 25 | $1.3B | $-15.1M | ||
| Q4 24 | $-22.0M | $-96.6M | ||
| Q3 24 | $1.6B | $-7.6M | ||
| Q2 24 | $1.4B | $-11.0M | ||
| Q1 24 | $1.4B | $-16.9M |
毛利率ABBVACRS
| Q4 25 | 72.6% | 58.9% | ||
| Q3 25 | 66.4% | 83.7% | ||
| Q2 25 | 71.8% | 71.0% | ||
| Q1 25 | 70.0% | 65.2% | ||
| Q4 24 | 70.9% | 92.3% | ||
| Q3 24 | 70.9% | 85.0% | ||
| Q2 24 | 70.9% | 77.4% | ||
| Q1 24 | 66.7% | 66.3% |
营业利润率ABBVACRS
| Q4 25 | 27.3% | -1755.5% | ||
| Q3 25 | 12.1% | -519.8% | ||
| Q2 25 | 31.7% | -1035.9% | ||
| Q1 25 | 28.0% | -1242.9% | ||
| Q4 24 | -9.9% | -1082.3% | ||
| Q3 24 | 26.5% | -240.9% | ||
| Q2 24 | 27.6% | -464.7% | ||
| Q1 24 | 22.7% | -789.4% |
净利率ABBVACRS
| Q4 25 | 10.9% | -1528.6% | ||
| Q3 25 | 1.2% | -443.0% | ||
| Q2 25 | 6.1% | -868.3% | ||
| Q1 25 | 9.6% | -1036.8% | ||
| Q4 24 | -0.1% | -1048.3% | ||
| Q3 24 | 10.8% | -174.6% | ||
| Q2 24 | 9.5% | -397.2% | ||
| Q1 24 | 11.1% | -706.5% |
每股收益（稀释后）ABBVACRS
| Q4 25 | $1.02 | $-0.16 | ||
| Q3 25 | $0.10 | $-0.12 | ||
| Q2 25 | $0.52 | $-0.13 | ||
| Q1 25 | $0.72 | $-0.12 | ||
| Q4 24 | $-0.03 | $-1.21 | ||
| Q3 24 | $0.88 | $-0.11 | ||
| Q2 24 | $0.77 | $-0.15 | ||
| Q1 24 | $0.77 | $-0.24 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.3B | $20.0M |
| 总债务越低越好 | $58.9B | — |
| 股东权益账面价值 | $-3.3B | $103.1M |
| 总资产 | $134.0B | $160.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ABBVACRS
| Q4 25 | $5.3B | $20.0M | ||
| Q3 25 | $5.7B | $25.3M | ||
| Q2 25 | $6.5B | $25.4M | ||
| Q1 25 | $5.2B | $30.4M | ||
| Q4 24 | $5.6B | $24.6M | ||
| Q3 24 | $7.3B | $47.7M | ||
| Q2 24 | $13.2B | $22.8M | ||
| Q1 24 | $18.1B | $35.8M |
总债务ABBVACRS
| Q4 25 | $58.9B | — | ||
| Q3 25 | $63.0B | — | ||
| Q2 25 | $63.0B | — | ||
| Q1 25 | $64.5B | — | ||
| Q4 24 | $60.3B | — | ||
| Q3 24 | $58.5B | — | ||
| Q2 24 | $58.0B | — | ||
| Q1 24 | $63.8B | — |
股东权益ABBVACRS
| Q4 25 | $-3.3B | $103.1M | ||
| Q3 25 | $-2.6B | $120.1M | ||
| Q2 25 | $-183.0M | $131.7M | ||
| Q1 25 | $1.4B | $144.1M | ||
| Q4 24 | $3.3B | $155.6M | ||
| Q3 24 | $6.0B | $130.2M | ||
| Q2 24 | $6.8B | $133.8M | ||
| Q1 24 | $8.0B | $142.0M |
总资产ABBVACRS
| Q4 25 | $134.0B | $160.5M | ||
| Q3 25 | $133.9B | $175.5M | ||
| Q2 25 | $137.2B | $189.1M | ||
| Q1 25 | $136.2B | $198.1M | ||
| Q4 24 | $135.2B | $220.3M | ||
| Q3 24 | $143.4B | $182.4M | ||
| Q2 24 | $141.9B | $161.1M | ||
| Q1 24 | $148.9B | $174.1M |
负债/权益比ABBVACRS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 45.44× | — | ||
| Q4 24 | 18.15× | — | ||
| Q3 24 | 9.70× | — | ||
| Q2 24 | 8.56× | — | ||
| Q1 24 | 7.97× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.2B | $-13.1M |
| 自由现金流经营现金流 - 资本支出 | $4.9B | $-13.2M |
| 自由现金流率自由现金流/营收 | 29.4% | -1015.8% |
| 资本支出强度资本支出/营收 | 2.0% | 1.9% |
| 现金转化率经营现金流/净利润 | 2.87× | — |
| 过去12个月自由现金流最近4个季度 | $17.8B | $-47.2M |
8季度趋势，按日历期对齐
经营现金流ABBVACRS
| Q4 25 | $5.2B | $-13.1M | ||
| Q3 25 | $7.0B | $-10.9M | ||
| Q2 25 | $5.2B | $-10.0M | ||
| Q1 25 | $1.6B | $-13.1M | ||
| Q4 24 | $7.0B | $-8.9M | ||
| Q3 24 | $5.4B | $22.0M | ||
| Q2 24 | $2.3B | $-12.3M | ||
| Q1 24 | $4.0B | $-20.8M |
自由现金流ABBVACRS
| Q4 25 | $4.9B | $-13.2M | ||
| Q3 25 | $6.6B | $-11.0M | ||
| Q2 25 | $4.9B | $-10.0M | ||
| Q1 25 | $1.4B | $-13.1M | ||
| Q4 24 | $6.8B | — | ||
| Q3 24 | $5.2B | — | ||
| Q2 24 | $2.0B | $-12.3M | ||
| Q1 24 | $3.8B | $-20.9M |
自由现金流率ABBVACRS
| Q4 25 | 29.4% | -1015.8% | ||
| Q3 25 | 42.1% | -332.1% | ||
| Q2 25 | 31.7% | -563.5% | ||
| Q1 25 | 10.5% | -900.3% | ||
| Q4 24 | 44.7% | — | ||
| Q3 24 | 35.9% | — | ||
| Q2 24 | 14.0% | -446.0% | ||
| Q1 24 | 31.3% | -873.6% |
资本支出强度ABBVACRS
| Q4 25 | 2.0% | 1.9% | ||
| Q3 25 | 2.4% | 0.7% | ||
| Q2 25 | 1.7% | 1.2% | ||
| Q1 25 | 1.8% | 3.0% | ||
| Q4 24 | 1.9% | 0.0% | ||
| Q3 24 | 1.7% | 0.0% | ||
| Q2 24 | 1.7% | 0.5% | ||
| Q1 24 | 1.6% | 5.6% |
现金转化率ABBVACRS
| Q4 25 | 2.87× | — | ||
| Q3 25 | 37.76× | — | ||
| Q2 25 | 5.49× | — | ||
| Q1 25 | 1.27× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.49× | — | ||
| Q2 24 | 1.66× | — | ||
| Q1 24 | 2.95× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
